Member Info for dryland

i see a 100k and a 350k buy @1.14p

Alistair said last night they are working this weekend

and they plan to achieve 30m tests per month:

https://twitter.com/AlanDuff3/status/1258387114460426241

looks like they want to raise $2.5b

@JCEP many thanks for sharing that if it all comes together the figures are mind boggling indeed

filtered....

Just for fun!

why will they want to play it? They earn their crust on the spread and with the amount of daily trades i think they are doing very well

it's done to stop volatility in the market which is a hellova joke really

:-)

i really do think this is one of those very rare life changing AIM opportunities..

i would be leathered already

are you listening to the presentation?

they are lab based tests

try this it looks like slides from the presentation https://twitter.com/MrFtrader/status/1257964517721546752/photo/2

we have all been there... i have never used a stop loss on AIM because if the sp is tanking there isnt much chance of it kicking in when you want and when the MM's are short its easy for them to drop the sp to pick up shares to fill orders. But i have sold in panic mode once or twice and regretted it....there is an art to just holding and with AVCT i find it much easier doing so than i would with a lot of the dross on AIM.

investor briefing started at 9.30 lets see if there's any feedback on that

10's of millions...obviously a typo should have read billions

Click on the filter tab just above the post message tab and enter the username you want to filter

'Full-year results (17 months) to 31 December 2019 were in line with expectations,
with a year-end cash balance of £8.8m (FC est. £8.7m). Despite the disruption
caused by the COVID-19 pandemic, Avacta has a cash runway into 2022'

this is from the opening salvo by FINNCAP:
Pursuing a
proprietary and partnership approach creates potential substantial incremental
value, as evidenced by the four therapeutic and three diagnostics partnerships,
whilst enabling Avacta to focus on its lead programme, which is now expected to
enter Phase I trials in late 2020 or early 2021. We consider Avacta to be at a very
exciting point in its evolution, with multiple significant valuation drivers.